VivoSeq
Dermatology

Scar

1

Pipeline Programs↗

7

Active Trials↗

5

Companies Involved↗

Scar is an early-stage landscape with 1 program across 5 companies. The most active players are Kringle Pharma, Inc., Eli Lilly, Mylan Pharmaceuticals Inc. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

19/100

Mech. Concentration

N/A

Completion Rate

88/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

K

Kringle Pharma, Inc.

1 program

Phase 3Eli Lilly logo

Eli Lilly

1 program

Phase 3Mylan Pharmaceuticals Inc logo

Mylan Pharmaceuticals Inc

0 programs

PreclinicalUltragenyx logo

Ultragenyx

0 programs

PreclinicalAstraZeneca logo

AstraZeneca

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 31

KP-100LI

Kringle Pharma, Inc.

Approved
No programs

Analysis

Trial Status

26

clinical trials

Completed14 · 54%
Recruiting3 · 12%
Unknown status3 · 12%
Active, not recruiting3 · 12%
Terminated2 · 8%
Not yet recruiting1 · 4%

Clinical Trials

Trial Activity

26 trials

Post-Operative Use of FS2 to Mitigate Scarring in Burn Patients
Recruiting·BBirch BioMed Inc·Phase 2/3·NCT06807021·70 enrolled
The Relation Between the Number of Previous Cesarean Sections and the Type of Scar Pregnancy: Observational Study
Recruiting·SSohag University·N/A·NCT07685158·70 enrolled
The Treatment Outcomes of Cesarean Scar Pregnancy
Recruiting·WWomen's Hospital School Of Medicine Zhejiang University·N/A·NCT07608094·82 enrolled
Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency
Active, not recruiting·Ultragenyx logoUltragenyx·Phase 3·NCT05345171·32 enrolled
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Confirmatory Study For Intracordal Administration Of KP-100LI In Patients With Vocal Fold Scar
Active, not recruiting·KKringle Pharma, Inc.·Phase 3·NCT05627648·62 enrolled
The Effect of Combined Treatment of PDL and Fractional Photothermolysis on the Cosmetic Appearance of Postsurgical Scars
Active, not recruiting·NNorthwestern University·Preclinical·NCT03057964·76 enrolled
Subcision With CO₂ Laser or PRP vs Subcision Alone in Atrophic Acne Scars
Not yet recruiting·—·N/A·NCT07199608·42 enrolled
Microneedling Plus the Universal Peel For Acne Scarring
Completed·EEnglewood Hospital and Medical Center·N/A·NCT02174393·15 enrolled
Study of EB-001 in Facial Scar Reduction
Completed·BBonti, Inc.·Phase 2·NCT03346902·12 enrolled
Use of Artefill® for Moderate to Severe Atrophic Acne Scar Correction
Completed·SSuneva Medical, Inc.·Phase 3·NCT01559922·175 enrolled
Adapalene 0.3% - Benzoyl Peroxide 2.5% Gel and Risk of Formation of Atrophic Acne Scars
Completed·GGalderma R&D·Phase 4·NCT02735421·67 enrolled
Evaluation of Long-Acting Muscarinic Antagonists in COPD
Completed·UUniversity of Dundee·Phase 4·NCT02039050·15 enrolled
Juvista (Avotermin) in Scars Following Varicose Vein Removal
Completed·RRenovo·Phase 2·NCT00430326·156 enrolled
Nanofat in Post Burn Scars on the Face
Completed·KKing Edward Medical University·N/A·NCT03352297·48 enrolled
Fed Study of Finasteride Tablets 5 mg and Proscar® Tablets 5 mg
Completed·Mylan Pharmaceuticals Inc logoMylan Pharmaceuticals Inc·Phase 1·NCT00650377·30 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)